Mml Investors Services, LLC Avadel Pharmaceuticals PLC Transaction History

Mml Investors Services, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$12.55 - $17.22 $339,477 - $465,800	27,050 Added 36.12%	101,931 $1.72 Million
Q4 2023 Feb 14, 2024	BUY	$9.64 - $14.59 $22,114 - $33,469	2,294 Added 3.16%	74,881 $1.06 Million
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $226,466 - $351,572	21,987 Added 43.45%	72,587 $748,000
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $131,440 - $255,440	15,500 Added 44.16%	50,600 $834,000
Q1 2023 May 12, 2023	BUY	$6.41 - $9.95 $6,410 - $9,950	1,000 Added 2.93%	35,100 $322,000
Q4 2022 Feb 13, 2023	BUY	$5.02 - $10.0 $5,020 - $10,000	1,000 Added 3.02%	34,100 $244,000
Q2 2022 Aug 12, 2022	BUY	$1.07 - $6.95 $5,457 - $35,445	5,100 Added 18.21%	33,100 $81,000
Q1 2022 May 13, 2022	BUY	$5.46 - $8.29 $152,880 - $232,119	28,000 New	28,000 $191,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Mml Investors Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Mml Investors Services, LLC with notifications on news.